2024-10-16 - Analysis Report
## Abbott Laboratories (ABT) Stock Analysis

**1. Performance Comparison with S&P 500 (VOO):**

Abbott Laboratories is a global healthcare company that develops, manufactures, and markets a wide range of medical devices, pharmaceuticals, and nutritional products.  

The stock has underperformed the S&P 500 (VOO) over the period considered. Its cumulative return is 107.9%, while VOO's is 135.82%. This results in a current relative divergence of -27.92, meaning it is lagging behind the S&P 500 by 27.92%. This value is 14.34% of the historical maximum divergence between the two.

**2. Recent Price Movements:**

* Closing Price: $116.12
* 5-Day Moving Average: $115.18
* 20-Day Moving Average: $114.29
* 60-Day Moving Average: $111.81

The stock is currently trading above all three moving averages, indicating potential upward momentum. 

**3. Technical Indicators:**

* RSI: 56.77 - The RSI indicates the stock is currently in a neutral zone, neither overbought nor oversold.
* PPO: 0.13 - The PPO suggests a potential bullish signal, as it is above zero.
* Delta_Previous_Relative_Divergence: -5.86 - This negative value indicates a recent short-term downtrend in relative divergence.
* Expected Return: 0.0% - This indicates that over the next five years, the stock is expected to perform in line with the S&P 500. 

**4. Recent Earnings and Outlook:**

| Date        | EPS   | Revenue     |
|-------------|-------|-------------|
| 2024-07-31 | 0.74  | 10.38 B$   |
| 2024-05-02 | 0.7   | 9.96 B$    |
| 2023-11-01 | 0.82  | 10.14 B$   |
| 2023-08-03 | 0.79  | 9.98 B$    |
| 2024-07-31 | 0.79  | 9.98 B$    |

The most recent earnings report for the quarter ending July 31st, 2024, showed EPS of $0.74, exceeding analysts' estimates. Revenue of $10.38 billion also beat expectations. This indicates that the company is performing well, exceeding market expectations.

**5. News and Recent Issues:**

* **Recent Market Outlook:** According to FINBOLD, Abbott Laboratories stock is currently rated as a "Strong Buy" by analysts. Several analysts have recently upgraded their ratings on the stock, citing strong financial performance and a positive outlook for the company's key businesses.
* **Analyst Opinions and Performance Highlights:**  Several analysts highlight Abbott's consistent track record of dividend growth, robust cash flow, and a diverse portfolio of products as key strengths. 
* **Recent Issues:** Abbott has recently faced regulatory scrutiny regarding its infant formula production, but the company has taken steps to address these concerns.

**6. Overall Analysis:**

Abbott Laboratories is a strong and established healthcare company with a diverse product portfolio. While its stock has recently underperformed the S&P 500, recent earnings have exceeded expectations, and analyst sentiment is positive. The stock's current price is trading above moving averages, suggesting potential upward momentum. The expected return of 0.0% indicates that the stock is projected to perform in line with the S&P 500 in the next five years. However, investors should monitor the company's regulatory issues and potential impact on its future growth.

**7. Report:**

Abbott Laboratories is a global healthcare company with a strong presence in the medical devices, pharmaceuticals, and nutritional products markets. The company's stock has recently underperformed the S&P 500, but recent earnings have exceeded expectations. Analysts remain optimistic about the company's future prospects, highlighting its strong track record of dividend growth, robust cash flow, and diverse product portfolio. The stock's price is currently trading above moving averages, suggesting potential upward momentum. However, investors should monitor the company's regulatory issues and potential impact on its future growth. Overall, Abbott Laboratories is a solid investment option for investors seeking exposure to the healthcare sector, with a strong track record of profitability and a bright outlook for the future.
